Literature DB >> 12393075

Total plasma homocysteine level and risk of cardiovascular disease: a meta-analysis of prospective cohort studies.

Leonelo E Bautista1, Iván A Arenas, Anderson Peñuela, Luz X Martínez.   

Abstract

The role of homocysteine as a risk factor for cardiovascular disease remains controversial because positive reports from case-control studies may be the consequence of reverse causality bias, and positive and negative results have been reported in cohort studies. This is a meta-analysis of published cohort studies. An average relative risk (ARR) was calculated using fixed and random effect models. The likelihood of publication and selection bias, and the impact of each study on the ARR were also evaluated. Fourteen eligible studies were retrieved. We found no evidence of publication bias (P =.62) nor heterogeneity (P =.56). The ARRs from a fixed effect model were 1.49 (95% CI: 1.31-1.70) for cardiac events, and 1.37 (95% CI: 0.99- 1.99) for ischemic stroke. Duration of follow up and age did not significantly change the ARRs. Hyperhomocysteinemia moderately increases the risk of a first cardiovascular event, regardless of age and follow-up duration.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12393075     DOI: 10.1016/s0895-4356(02)00434-1

Source DB:  PubMed          Journal:  J Clin Epidemiol        ISSN: 0895-4356            Impact factor:   6.437


  30 in total

1.  Elevated homocysteine levels and risk of cardiovascular and all-cause mortality: a meta-analysis of prospective studies.

Authors:  Hui-yong Peng; Chang-feng Man; Juan Xu; Yu Fan
Journal:  J Zhejiang Univ Sci B       Date:  2015-01       Impact factor: 3.066

2.  Impact of voluntary folate fortification on plasma homocysteine and serum folate in Australia from 1995 to 2001: a population based cohort study.

Authors:  Siobhan Hickling; Joseph Hung; Matthew Knuiman; Konrad Jamrozik; Brendan McQuillan; John Beilby; Peter Thompson
Journal:  J Epidemiol Community Health       Date:  2005-05       Impact factor: 3.710

Review 3.  Homocysteine and atherothrombosis: diagnosis and treatment.

Authors:  Diane E Handy; Joseph Loscalzo
Journal:  Curr Atheroscler Rep       Date:  2003-07       Impact factor: 5.113

4.  Matrix imbalance by inducing expression of metalloproteinase and oxidative stress in cochlea of hyperhomocysteinemic mice.

Authors:  Soumi Kundu; Neetu Tyagi; Utpal Sen; Suresh C Tyagi
Journal:  Mol Cell Biochem       Date:  2009-07-10       Impact factor: 3.396

5.  The atherogenic effect of excess methionine intake.

Authors:  Aron M Troen; Esther Lutgens; Donald E Smith; Irwin H Rosenberg; Jacob Selhub
Journal:  Proc Natl Acad Sci U S A       Date:  2003-12-01       Impact factor: 11.205

6.  Cobalamin deficiency, hyperhomocysteinemia, and dementia.

Authors:  Steven F Werder
Journal:  Neuropsychiatr Dis Treat       Date:  2010-05-06       Impact factor: 2.570

7.  Homocysteine, B vitamins, and the incidence of dementia and cognitive impairment: results from the Sacramento Area Latino Study on Aging.

Authors:  Mary N Haan; Joshua W Miller; Allison E Aiello; Rachel A Whitmer; William J Jagust; Dan M Mungas; Lindsay H Allen; Ralph Green
Journal:  Am J Clin Nutr       Date:  2007-02       Impact factor: 7.045

8.  Atorvastatin attenuates homocysteine-induced apoptosis in human umbilical vein endothelial cells via inhibiting NADPH oxidase-related oxidative stress-triggered p38MAPK signaling.

Authors:  Xiao-mei Bao; Chun-fang Wu; Guo-ping Lu
Journal:  Acta Pharmacol Sin       Date:  2009-09-21       Impact factor: 6.150

9.  Methionine-deficient diet induces post-transcriptional downregulation of cystathionine β-synthase.

Authors:  Baiqing Tang; Aladdin Mustafa; Sapna Gupta; Stepan Melnyk; S Jill James; Warren D Kruger
Journal:  Nutrition       Date:  2009-12-29       Impact factor: 4.008

10.  Plasma folate, but not homocysteine, is associated with Apolipoprotein A1 levels in a non-fortified population.

Authors:  Elisabet Söderström; Mats Eliasson; Owe Johnson; Göran Hallmans; Lars Weinehall; Jan-Håkan Jansson; Johan Hultdin
Journal:  Lipids Health Dis       Date:  2013-05-22       Impact factor: 3.876

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.